Articles tagged with Small Interfering Rna
CSHL researchers have found that changes in small RNA patterns enable transposons to re-activate in continuously dividing cells, leading to genomic instability and potential disease consequences. The team's study implicates RNA interference in epigenetic chromatin changes that occur in immortalized cells.
Nucleolar dominance is a phenomenon where an entire parental set of ribosomal RNA genes are silenced in hybrid plants or animals. Researchers have made a breakthrough in understanding this process, which may have important implications for cancer research.
A new study suggests that short interfering RNAs (siRNAs) may exhibit non-specific therapeutic effects related to immune stimulation. The researchers used a mouse model of influenza and demonstrated that the anti-viral activity of siRNA is mainly due to non-specific stimulation of the immune system.
Researchers have discovered a single dose of small interfering RNA (siRNA) can significantly reduce cholesterol levels in rodents, with effects lasting for weeks. The siRNA works by blocking the production of PCSK9, a protein that raises LDL cholesterol, and has shown promise in nonhuman primates as well.
Researchers at Harvard Medical School have successfully used RNA interference (RNAi) to prevent the spread of HIV in mice. The study found that knocking down three specific genes in T cells protected them from the virus, preventing it from jumping between cells.
Scientists have successfully used quantum dots to deliver gene-silencing tools (siRNA) into cells, achieving 2% protein production compared to 13-51% with existing methods. The new approach is also five-to-ten times less toxic to cells.
A UK physician's groundbreaking study reveals that siRNA therapies may have unintended consequences, such as blocking blood vessel growth in various organs. This discovery underscores the need for cautious approach in clinical trials using gene silencing technology.
A protein called interleukin-8 (IL-8) promotes tumor growth and angiogenesis in ovarian cancer. Researchers have identified IL-8 as a therapeutic target and tested short interfering RNA (siRNA) to silence its production, reducing tumor size by attacking its blood supply.
Researchers at ETH Zurich have elucidated a mechanism for the uptake of small interfering RNAs (siRNAs) in mammals, which involves conjugation with fatty acids and binding to lipophilic proteins like HDL and LDL. The discovery has significant implications for siRNA therapies and gene regulation.
Scientists have developed a new method to deliver therapeutic molecules across the blood-brain barrier using a short protein from the rabies virus. This approach protects mice from infection caused by the Japanese encephalitis virus, suggesting potential for treating various brain infections and diseases.
Researchers have developed targeted nanoparticles incorporating siRNA that can slow tumor growth without eliciting toxicities. The nanoparticles' structure and biological function are characterized using physicochemical and biological methods, offering insights into designing more effective carriers.
Researchers successfully tested a new method of treatment for fatal brain diseases like scrapie and Creutzfeld-Jakob, slowing disease progression by up to 97% in mice. The approach uses RNA interference to reduce production of the pathogenic prion protein.
Researchers at Washington University in St. Louis have identified a pathway that enables plant cells to silence unwanted genes using short interfering RNAs. The study reveals the roles of eight proteins in this process, which involves DNA methylation and epigenetic regulation.
Researchers have developed a new approach to target different diseases using short interfering RNA (siRNA) with tailored cellular properties. Human trials for siRNA-based anti-cancer and anti-viral treatments are currently underway in the USA and Europe, offering promising results.
Members of RNAi Global, including Dharmacon and leading research institutes, developed standardized protocols for genome-wide siRNA library experiments. The collaboration aims to accelerate disease and drug research by improving comparability of results between laboratories.
Researchers used small interfering RNAs to block the spread of human colorectal cancer cells in laboratory mice, achieving a major reduction in liver cancer growth. The treatment also showed potential for increased cancer cell killing when combined with standard chemotherapeutic agents.
Researchers at Children's Hospital of Philadelphia developed a novel lab technique to manipulate human T cells using RNA interference, overcoming previous limitations. The approach successfully silenced genes in 'slippery' immune cells, opening potential avenues for treating HIV and other diseases.
Researchers have gained a detailed understanding of Dicer's molecular structure, which serves as a 'molecular ruler' for processing RNA fragments. This discovery has significant implications for gene-silencing processes and could lead to new treatments for diseases.
Scientists have discovered that human cells use RNA silencing to defend against HIV, a phenomenon previously unknown in mammals. The discovery of a novel siRNA sequence that targets the HIV protein Tat may lead to the development of new RNAi-based drugs to combat the virus.
Researchers have developed a novel delivery system that uses siRNA to silence the growth-promoting gene EWS-FLI1 in tumor cells, effectively inhibiting cell replication by 80%. The nanoparticles are designed to target specific tumor sites and avoid degradation, making them a promising treatment option for Ewing's sarcoma.
Researchers investigated polo like kinase-1 (PLK-1) siRNA in mice with bladder cancer, finding that intravesical administration of the inhibitor reduced cell proliferation and killed cancer cells. PLK-1 siRNA also prevented growth of bladder cancer in mouse models.
Researchers at UCSD and VA San Diego Healthcare System have developed a novel method of transcriptional gene silencing in the nucleus, utilizing short interfering RNA (siRNA). This approach may provide a long-lasting solution for gene regulation, with potential applications in treating diseases such as cancer and HIV.
Researchers develop system to study small RNAs using siRNA inhibitors, providing unprecedented insight into RNA interference and microRNA functions. The technique enables rapid discovery of hundreds of microRNAs' regulatory roles, with significant implications for genetic studies.
A Stanford team has developed a simplified method for generating siRNA molecules to disable genes, overcoming the technique's limitations in expense and labor. The new protocol allows researchers to create libraries of siRNA molecules for all known genes, enabling the identification of genes that play critical roles in stem cell function.
Researchers have successfully created a delivery system using a vehicle derived from HIV itself to introduce synthetic siRNAs into human cells. This approach aims to prevent HIV infection by knocking out the CCR5 receptor, which is found on T-cells and plays a role in immune function.
Scientists have discovered a new method to inhibit HIV replication using short interfering RNAs (siRNAs), a type of RNA interference technology. Researchers demonstrated the effectiveness of siRNAs in human cells, showing promise for novel HIV treatments.
Researchers have developed a new genetic technique that can deliver a knockout blow to the Asthma Virus by targeting its RNA. The technique, called post-translational gene silencing, uses specific siRNA molecules to block viral protein production and suppress virus replication.